Bladder cancer--current management
Related Experiment Video
Updated: Jun 1, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Ranjan Arianayagam1, Mohan Arianayagam, Prem Rashid
1Royal North Shore Hospital, Sydney, New South Wales. ranjan.arianayagam@gmail.com
Background:
Over 2000 cases of bladder cancer were diagnosed in Australia in 2005. Bladder cancer is a relatively common disease with high morbidity if left untreated. Bladder cancer is categorised as either 'nonmuscle invasive bladder cancer' or 'muscle invasive bladder cancer'. Treatment varies significantly for each type.
Objective:
This article provides an update on the presentation of bladder cancer, its risk factors, investigations and treatment, and discusses the role of chemotherapy as a neoadjuvant and adjuvant treatment.
Discussion:
Bladder cancer most commonly presents with microscopic or macroscopic haematuria. Evaluation is required of all patients with macroscopic haematuria, patients with persistent microscopic haematuria, and at risk patients with a single episode of microscopic haematuria. Evaluation consists of imaging, urine cytology and cystoscopy. Nonmuscle invasive bladder cancer patients can undergo tumour resection with adjuvant intravesical treatments, while muscle invasive bladder cancer patients are optimally treated with cystectomy and urinary diversion.
Related Concept Videos
Urinary Tract Calculi V: Nursing Management
Urinary Tract Calculi III: Medical Management
Urinary Tract Infection IV: Nursing Management
Urinary Tract Calculi VI: Surgical Management
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Imaging Studies VI: Voiding Cystourethrography and Cystography
